Učitavanje...
OP17. Measuring and modifying Temozolomide delivery in brain tumours
INTRODUCTION: Malignant brain tumours constitute a fatal diagnosis with 5-year survival rates of less than 5%. Temozolomide (TMZ) is the central chemotherapy agent used in the treatment of malignant brain tumours; however, despite aggressive treatment approaches outcomes are still poor with many pat...
Spremljeno u:
| Izdano u: | Neuro Oncol |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Oxford University Press
2017
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5358586/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now292.016 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|